Amy L. Pasternak
Pharmacology, Toxicology and Pharmaceutics · University of Michigan
Publications
52
Citations
597
Est. group size
~5
Recurring co-author estimate
Active years
27
Publishing since 2000
Typically publishes in teams of ~5 · 39% small-team papers (≤3 authors) · across 10 venues
- Association of uncommon <i>DPYD</i> polymorphisms with severe fluoropyrimidine toxicity.
Journal of Clinical Oncology · 2026
- Association of Genetic Variation in CES, UGT, ABC, and SLCO with Irinotecan Infusion Reactions and Severe Toxicity: Erratum
Pharmacogenetics and Genomics · 2026
- Survey of the utilization of genotype-guided tacrolimus management in United States solid organ transplant centers
Pharmacogenomics · 2025
- Association of genetic variation with irinotecan infusion reactions and severe toxicity
Pharmacogenetics and Genomics · 2025
- Association of Genetic Variation in CES, UGT, ABC, and SLCO with Irinotecan Infusion Reactions and Severe Toxicity: Corrigendum
Pharmacogenetics and Genomics · 2025
- CYP3A5 pharmacogenetic testing for tacrolimus in pediatric heart transplant patients: a budget impact analysis
Pharmacogenetics and Genomics · 2024
- The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2024
- Pharmacogenetic Considerations for Irinotecan Therapy
SMART-MD journal of precision medicine. · 2024
- Risk of Toxicity From Topical <scp>5‐Fluorouracil</scp> Treatment in Patients Carrying <i>DPYD</i> Variant Alleles
Clinical Pharmacology & Therapeutics · 2023
- Risk of severe toxicity from topical fluoropyrimidine treatment in patients carrying <i>DPYD</i> variant alleles.
Journal of Clinical Oncology · 2023
- Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients
Therapeutic Drug Monitoring · 2022
- Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2021
- SLCO1B3 Polymorphisms and Clinical Outcomes in Kidney Transplant Recipients Receiving Mycophenolate
Pharmacogenomics · 2021
- Patient-customized oligonucleotide therapy for a rare genetic disease
Yearbook of pediatric endocrinology · 2020
- The Future of Research into Genetics and the Precision Dosing of Tacrolimus: What do we Need to Know?
Pharmacogenomics · 2020
- Pharmacogenomics×8
- Pharmacogenetics and Genomics×6
- Neuro-Oncology×5
- JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY×3
- Clinical and Translational Science×2
- Tyler Shugg
Pharmacology, Toxicology and Pharmaceutics · Indiana University
- Reynold C. Ly
Pharmacology, Toxicology and Pharmaceutics · Indiana University
- Stephan Schmidt
Pharmacology, Toxicology and Pharmaceutics · The Ohio State University
- Emily E. Scott
Pharmacology, Toxicology and Pharmaceutics · University of Michigan
- Aditi Shendre
Pharmacology, Toxicology and Pharmaceutics · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile